Carly Forster


Urban Outfitters Outperforms Q4 Amidst Offensive Tapestry Controversy

Urban Outfitters (NASDAQ: URBN) shares rose 7% in after-hours trading on Monday, February 9th following the company’s impressive revenue and same-store sale results for the …

Cannacord Genuity Boosts Price Target on Apple

Apple (NASDAQ: AAPL) broke records on January 27th after the company posted an $18 billion profit made in its fourth quarter of 2014. The main …

Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) jumped almost 20% in trading on February 9th after the company announced positive interim data results for its hepatitis …

Analyst is Bearish on Shake Shack in Favor of The Habit

Popular upscale hamburger chain Shake Shack (NYSE: SHAK) announced its highly coveted IPO on January 30th, pricing shares at $21 to start. Investors were …

Looking Ahead of Wall Street: Coca-Cola, PepsiCo, CVS Health

Wall Street has an exciting week ahead as the two biggest beverage companies, Coca Cola and PepsiCo, are set to battle it out …

Disney Reports Stellar Earnings Attributed to Frozen

Known as the company behind everyone’s favorite mouse, Walt Disney (NYSE: DIS) had investors singing “zippidy do-da” after announcing stellar results from its first …

Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015

Gilead Sciences (NASDAQ: GILD) dropped roughly 10% in morning trading on Wednesday, February 4th following the announcement of its fourth quarter 2014 earnings results the …

Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals

hares of IntelliPharmaceutics International  (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …

Analysts Chime in on Under Armour Ahead of Q4’14 Earnings

Sportswear and casual apparel retailer Under Armour (NYSE: UA) is set to announce earnings for the final quarter of 2014 on Wednesday, February 4th after …

Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results

Medivation (NASDAQ: MDVN) is best known for developing therapies to treat serious diseases. Earlier in 2014 the biopharmaceutical company received FDA approval to expand …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts